Patricia Zahner, MD
Urogynecology and Reconstructive Pelvic Surgery · Moorestown, NJNPI 1023307386
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,829 of the $7,876 with a category attached, or 74.0%. 29 manufacturers reported payments, led by Medtronic at 34.0% of the total. Reporting peaked in 2024 at $2,454 and has fallen 50.9% since, to $1,205 in 2025.
Across 201 payments — averaging $39.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Bluewind Medical$2K
- Boston Scientific$418
- Astellas Pharma US Inc$386
- Sumitomo Pharma America, Inc.$339
- Axonics, Inc.$326
- plus $2K from 23 others
Across 1 payment — averaging $710.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$710
What the payments were for
- Travel & lodging$2,04626%
- Food & beverage$5,82974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 56 | $2,680 |
| Bluewind Medical | 10 | $1,632 |
| Boston Scientific | 11 | $418 |
| Astellas Pharma US Inc | 17 | $386 |
| Sumitomo Pharma America, Inc. | 17 | $339 |
| Axonics, Inc. | 7 | $326 |
| Caldera Medical, Inc | 4 | $316 |
| Coloplast | 11 | $262 |
| Convatec Inc. | 8 | $249 |
| Endo Pharmaceuticals Inc. | 13 | $221 |
| Antares Pharma, Inc. | 7 | $161 |
| AbbVie | 8 | $161 |
| Valencia Technologies Corporation | 5 | $139 |
| Urovant Sciences Inc | 6 | $111 |
| Dentsply IH AB | 2 | $84 |
| Millicent US Inc | 2 | $41 |
| Bard Access Systems, Inc. | 1 | $41 |
| Halozyme Inc | 2 | $39 |
| Bayer | 2 | $39 |
| Johnson & Johnson | 2 | $38 |
| Photocure Inc | 2 | $33 |
| Myovant Sciences Inc. | 1 | $30 |
| Avation Medical, Inc. | 1 | $27 |
| Telix Pharmaceuticals | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Urogen Pharma, Inc. | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,876 in reported general payments places this provider in the 70th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
See all urogynecology and reconstructive pelvic surgery providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 511 | $371,126 |
| MyrbetriqMirabegron | 182 | $153,414 |
| Estradiol | 580 | $32,257 |
| EstringEstradiol | 44 | $22,952 |
| Trospium Chloride ErTrospium Chloride | 113 | $14,231 |
| Mirabegron ErMirabegron | 14 | $7,693 |
| Solifenacin Succinate | 147 | $5,880 |
| Methenamine Hippurate | 73 | $5,450 |
| YuvafemEstradiol | 17 | $2,535 |
| Oxybutynin Chloride ErOxybutynin Chloride | 49 | $1,474 |
| Trospium Chloride | 33 | $1,446 |
| Trimethoprim | 18 | $1,333 |
| NitrofurantoinNitrofurantoin Macrocrystal | 57 | $1,223 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 92 | $918 |
| CefuroximeCefuroxime Axetil | 41 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $339 | $371,126511 claims |
| Astellas Pharma US IncMyrbetriq | $386 | $153,414182 claims |
| PfizerEstring | $15 | $22,95244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
Other urogynecology and reconstructive pelvic surgery in Moorestown
- Nina BhatiaManalapan$77K
- Debra FromerHackensack$50K
- Donald DebrakeleerPennington$36K
- Uzma ChaudhryTrenton$14K
- Alexander BergerCherry Hill$14K
- Kristene WhitmoreCherry Hill$13K
- Betsy GreenleafHowell$11K
- Sandy NosseirMarlton$11K
- Gary MironeCape May Court House$9K
- Anna PancheshnikovVoorhees$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.